MktsMarkets

Akari Therapeutics Plc
NASDAQ: AKTXKey statistics
AKTX News
Stories mentioning AKTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,459 | 1,086 | 249.00 | 667.00 | 813.00 | 1,247 | 143.00 | 3,314 |
| Sales General & Admin | 2,169 | 2,141 | 1,975 | 2,452 | 2,712 | 2,004 | 1,709 | 2,241 |
| Total Operating Expenses | 15,758 | 3,525 | ||||||
| Operating Income (Loss) | (15,758) | (3,227) | (7,404) | (3,119) | (3,525) | (5,278) | (2,927) | (7,449) |
| Interest Income | 1.00 | 1.00 | 3.00 | 2.00 | ||||
| Interest Expense | 100.00 | 51.00 | ||||||
| Other Expense | ||||||||
| Pretax Income | (15,314) | (7,488) | (3,705) | (2,895) | ||||
| Tax Provision | (859.00) | 85.00 | (1,088) | 0.00 | 0.00 | |||
| Net Income (Loss) | (14,455) | (5,298) | (6,400) | (1,895) | (3,705) | (3,772) | (2,895) | (7,558) |
| Earnings Per Share (Basic) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings Per Share (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Average Shares Outstanding (Basic) | 118,757,013 | 67,328,129 | 65,326,237 | 62,943,896 | 54,588,284 | 23,888,010 | 24,386,006 | 18,836,479 |
| Weighted Average Shares Outstanding (Diluted) | 118,757,013 | 67,328,129 | 65,326,237 | 62,943,896 | 54,588,284 | 23,888,010 | 24,386,006 | 18,836,479 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About AKTX
Akari Therapeutics Plc (NASDAQ: AKTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol AKTX. It last traded at $6.80 (Nov 13, 2026, 3:30 PM ET), up 4.5% on the day. That gives Akari Therapeutics a market capitalisation of $11.4M.
Over the past 52 weeks AKTX has traded between $3.02 and $29.32.
For the quarter ended Mar 31, 2026 it reported a net loss of $14.5M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$14.5M |
| Dec 31, 2025 | — | -$5.3M |
| Sep 30, 2025 | — | -$6.4M |
| Jun 30, 2025 | — | -$1.9M |
From Akari Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…